Drug Deliv Transl Res. 2021 Jan 23; doi: 10.1007/s13346-021-00899-5. Epub 2021 Jan 23.

Pluronic F127-tailored lecithin organogel of acyclovir: preclinical evidence of antiviral activity using BALB/c murine model of cutaneous HSV-1 infection.

Drug delivery and translational research

Gajanand Sharma, Bimaldeep Kaur, Kanika Thakur, Akanksha Mahajan, Basant Amarji, Mini P Singh, Om Prakash Katare

PMID: 33486688 DOI: 10.1007/s13346-021-00899-5

Abstract

Herpes is a well-known contagious infection equally affecting both sexes. Among many antiviral drugs employed for its treatment, acyclovir (ACY) is the drug of choice. The currently available therapies of ACY suffer from limitations like poor oral bioavailability (10-15%) and high-dose requirement. The present scientific study aims to explore pluronic lecithin organogel (PLO) as a novel drug delivery platform for ACY to bring an improvement in its delivery through topical route. The properties of organogel like biocompatibility and amphiphilic nature which facilitates dissolution of various drugs of different solubility characteristics along with enhancing the permeation potential of active molecules make it a favorable drug delivery platform for the management of topical diseases. The developed PLO formulations were characterized for micromeritic characteristics, viz., zeta potential, percentage drug content, organogel morphology, skin permeation, retention, and stability studies. The selected topical formulation was further compared with the marketed one for its therapeutic efficacy by inducing cutaneous Herpes simplex virus type 1 infection followed by confirmation of viral load by immunofluorescence and PCR analyses. The developed formulation showed significant improvement over the marketed product as reflected in lesion scoring index and PCR analysis. Further, it proved better to the marketed formulation in t.i.d. treatment regimen in comparison to control. The improvement in overall performance leading to enhanced bioavailability and safety is attributed to the synergism between excipient properties and formulation characteristics. The drug ACY in this micro environment not only finds an improved delivery vehicle but it also offers enhanced drug-target interactions.

Keywords: Acyclovir; Herpes simplex virus (HSV-1); Immunofluorescence assay (IFA); Polymerase chain reaction (PCR)

References

1. Roizman B, Knipe DM, Whitley R. Herpes simplex viruses. In: Knipe DM, Howley P, editors. Fields Virology. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2007. p. 2501–601. - PubMed
2. Whitley RJ, Roizman B. Herpes simplex virus infections. The Lancet. 2001;357:1513–8. - PubMed
3. Bean B. Acyclovir in the treatment of herpe svirus infections. Postgrad Med J. 1983;73:297–303. - PubMed
4. Sharma G, Thakur K, Setia A, Amarji B, Singh MP, Raza K, et al. Fabrication of acyclovir-loaded flexible membrane vesicles (FMVs): evidence of preclinical efficacy of antiviral activity in murine model of cutaneous HSV-1 infection. Drug Delivery and Translational Research. 2017;7:683–94. - PubMed
5. Kaur A, Sharma G, Gupta V, Ratho RK, Katare OP. Enhanced acyclovir delivery using w/o type microemulsion: preclinical assessment of antiviral activity using murine model of zosteriform cutaneous HSV-1 infection. Artif Cells Nanomed Biotechnol. 2018;46:346–54. - PubMed
6. Cortesi R, Esposito E. Acyclovir delivery systems. Expert Opin Drug Deliv. 2008;5:1217–30. - PubMed
7. Fireman S, Toledano O, Neimann K, Loboda N, Dayan N. A look at emerging delivery systems for topical drug products. Dermatol Ther. 2011;24:477–88. - PubMed
8. Nair AB. Quantification of uptake and clearance of acyclovir in skin layers. Antivir Ther. 2016;21:17–25. - PubMed
9. Freeman DJ, Sheth NV, Spruance SL. Failure of topical acyclovir in ointment to penetrate human skin. Antimicrob Agents Chemother. 1986;29:730–2. - PubMed
10. Kumar R, Katare OP. Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: a review. AAPS PharmSciTech. 2005;6:E298–310. - PubMed
11. Sharma G, Devi N, Thakur K, Jain A, Katare OP. Lanolin-based organogel of salicylic acid: evidences of better dermatokinetic profile in imiquimod-induced keratolytic therapy in BALB/c mice model. Drug Deliv Transl Res. 2018;8:398–413. - PubMed
12. Almeida H, Amaral MH, Lobao P, Lobo JM. Pluronic(R) F-127 and Pluronic Lecithin Organogel (PLO): main features and their applications in topical and transdermal administration of drugs. J Pharm Pharm Sci. 2012;15:592–605. - PubMed
13. Pandey M, Belgamwar V, Gattani S, Surana S, Tekade A. Pluronic lecithin organogel as a topical drug delivery system. Drug Deliv. 2010;17:38–47. - PubMed
14. Alsaab H, Bonam SP, Bahl D, Chowdhury P, Alexander K, Boddu SH. Organogels in drug delivery: a special emphasis on pluronic lecithin organogels. J Pharm Pharm Sci. 2016;19:252–73. - PubMed
15. Barichello JM, Morishita M, Takayama K, Nagai T. Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm. 1999;184:189–98. - PubMed
16. Sharma G, Devi N, Thakur K, Jain A, Katare OP. Lanolin-based organogel of salicylic acid: evidences of better dermatokinetic profile in imiquimod-induced keratolytic therapy in BALB/c mice model. Drug Deliv Transl Res. 2017;  https://doi.org/10.1007/s13346-017-0364-9 - PubMed
17. Sharma G, Dhankar G, Thakur K, Raza K, Katare OP. Benzyl benzoate-loaded microemulsion for topical applications: enhanced dermatokinetic profile and better delivery promises. AAPS PharmSciTech. 2016;17:1221–31. - PubMed
18. Yadav NK, Nanda S, Sharma G, Katare OP. Systematically optimized ketoprofen-loaded novel proniosomal formulation for periodontitis: in vitro characterization and in vivo pharmacodynamic evaluation. AAPS PharmSciTech. 2017;18:1863–80. - PubMed
19. Chhibber T, Wadhwa S, Chadha P, Sharma G, Katare OP. Phospholipid structured microemulsion as effective carrier system with potential in methicillin sensitive Staphylococcus aureus (MSSA) involved burn wound infection. J Drug Target. 2015;1–10. - PubMed
20. Yadav NK, Nanda S, Sharma G, Katare OP. Systematically optimized coenzyme q10-loaded novel proniosomal formulation for treatment of photo-induced aging in mice: characterization, biocompatibility studies, biochemical estimations and anti-aging evaluation. J Drug Target. 2016;24:257–71. - PubMed
21. Bhatia A, Singh B, Raza K, Wadhwa S, Katare OP. Tamoxifen-loaded lecithin organogel (LO) for topical application: development, optimization and characterization. Int J Pharm. 2013;444:47–59. - PubMed
22. ICH. Q1A(R2) Stability testing of new drug substances and products, In: International Conference on Harmonisation, IFPMA, Geneva, 2003. - PubMed
23. Thakur K, Mahajan A, Sharma G, Singh B, Raza K, Chhibber S, et al. Implementation of Quality by Design (QbD) approach in development of silver sulphadiazine loaded egg oil organogel: an improved dermatokinetic profile and therapeutic efficacy in burn wounds. Int J Pharm. 2020;576:118977. - PubMed
24. Heck R, Lukic MZ, Savic SD, Daniels R, Lunter DJ. Ex vivo skin permeation and penetration of nonivamide from and in vivo skin tolerability of film-forming formulations containing porous silica. Eur J Pharm Sci. 2017;106. - PubMed
25. Sharma G, Saini MK, Thakur K, Kapil N, Garg NK, Raza K, et al. Aceclofenac cocrystal nanoliposomes for rheumatoid arthritis with better dermatokinetic attributes: a preclinical study. Nanomedicine (Lond). 2017;12:615–38. - PubMed
26. Sharma G, Kaur M, Raza K, Thakur K, Katare OP. Aceclofenac–β-cyclodextrin-vesicles: a dual carrier approach for skin with enhanced stability, efficacy and dermatokinetic profile. RSC Advances. 2016;6:20713–27. - PubMed
27. Verma DD, Verma S, Blume G, Fahr A. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm. 2003;258:141–51. - PubMed
28. Sharma G, Beg S, Thanki K, Katare OP, Jain S, Kohli K, et al. Systematic development of novel cationic self-nanoemulsifying drug delivery systems of candesartan cilexetil with enhanced biopharmaceutical performance. RSC Advances. 2015;5:71500–13. - PubMed
29. Rajpoot K. Acyclovir-loaded sorbitan esters-based organogel: development and rheological characterization. Artif Cells Nanomed Biotechnol. 2017;45:551–9. - PubMed
30. Sharma G, Goyal H, Thakur K, Raza K, Katare OP. Novel elastic membrane vesicles (EMVs) and ethosomes-mediated effective topical delivery of aceclofenac: a new therapeutic approach for pain and inflammation. Drug Delivery. 2016;23:3135–45. - PubMed
31. Craig MI, Benencia F, Coulombie FC. Antiviral activity of an acidic polysaccharides fraction extracted from Cedrela tubiflora leaves. Fitoterapia. 2001;72:113–9. - PubMed
32. Orlowski P, Tomaszewska E, Gniadek M, Baska P, Nowakowska J, Sokolowska J, et al. Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection. PLoS ONE. 2014;9:e104113. - PubMed
33. Simmons A, Nash AA. Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. J Virol. 1984;52:816–21. - PubMed
34. Iwayama S, Ohmura Y, Suzuki K, Ono N, Nakazawa H, Aoki M, et al. Evaluation of anti-herpesvirus activity of (1’S,2’R)-9-[[1’,2’-bis(hydroxymethyl)cycloprop-1’-yl]methyl]guanine (A-5021) in mice. Antiviral Res. 1999;42:139–48. - PubMed
35. Kurokawa M, Nagasaka K, Hirabayashi T, Uyama S, Sato H, Kageyama T, et al. Efficacy of traditional herbal medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo. Antiviral Res. 1995;27:19–37. - PubMed
36. Sheridan J, Kern E, Martin A, Booth A. Evaluation of antioxidant healing formulations in topical therapy of experimental cutaneous and genital herpes simplex virus infections. Antiviral Res. 1997;36:157–66. - PubMed
37. Piret J, Lamontagne J, Desormeaux A, Bergeron MG. Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1. Antimicrob Agents Chemother. 2001;45:1030–6. - PubMed
38. Rechter S, Konig T, Auerochs S, Thulke S, Walter H, Dornenburg H, et al. Antiviral activity of Arthrospira-derived spirulan-like substances. Antiviral Res. 2006;72:197–206. - PubMed
39. Wald A, Huang M, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis. 2003;188:1345–51. - PubMed
40. Fredricks DN, Relman DA. Application of polymerase chain reaction to the diagnosis of infectious diseases. Clin Infect Dis. 1999;29:475–86. - PubMed
41. Pal K, Banthia A, Majumdar D. Polyvinyl alcohol—gelatin patches of salicylic acid: preparation, characterization and drug release studies. J Biomater Appl. 2006;21:75–91. - PubMed
42. Nie S, Hsiao WL, Pan W, Yang Z. Thermoreversible Pluronic(®) F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomedicine. 2011;6:151–66. - PubMed
43. Visalli RJ, Courtney Rj, Meyers C. Infection and replication of herpes simplex virus type 1 in an organotypic epithelial culture system. Virology. 1997;230:236–43. - PubMed
44. Jarvis CA, McGuigan C, Heard CM. In vitro delivery of novel, highly potent anti-varicella zoster virus nucleoside analogues to their target site in the skin. Pharm Res. 2004;21:914–9. - PubMed
45. Hasler-Nguyen N, Shelton D, Ponard G, Bader M, Schaffrik M, Mallefet P. Evaluation of the in vitro skin permeation of antiviral drugs from penciclovir 1% cream and acyclovir 5% cream used to treat herpes simplex virus infection. BMC Dermatol. 2009;9. - PubMed
46. El Maghraby GM. Self-microemulsifying and microemulsion systems for transdermal delivery of indomethacin: effect of phase transition. Colloids Surf B Biointerfaces. 2010;75:595–600. - PubMed
47. Nguyen DV, Li F, Li H, Wong BS, Low CY, Liu XY, et al. Drug permeation through skin is inversely correlated with carrier gel rigidity. Mol Pharm. 2015;12:444–52. - PubMed
48. Hussain A, Samad A, Singh SK, Ahsan MN, Haque MW, Faruk A, et al. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation. Drug Deliv. 2016;23:642–7. - PubMed
49. Quenelle DC, Lampert B, Collins DJ, Rice TL, Painter GR, Kern ER. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis. 2010;202:1492–9. - PubMed
50. Verma DD, Fahr A. Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A. J Control Release. 2004;97:55–66. - PubMed

Publication Types

• Journal Article